PharmaCielo Ltd.
PCLOF
$0.0478
-$0.0067-12.29%
Weiss Ratings | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | E | |||
Rating Factors | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Very Weak | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.85 | |||
Price History | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -22.02% | |||
30-Day Total Return | -28.66% | |||
60-Day Total Return | -33.05% | |||
90-Day Total Return | -34.34% | |||
Year to Date Total Return | -15.40% | |||
1-Year Total Return | -54.82% | |||
2-Year Total Return | -66.76% | |||
3-Year Total Return | -91.88% | |||
5-Year Total Return | -88.71% | |||
52-Week High % Change | -78.27% | |||
52-Week Low % Change | 8.64% | |||
Price | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.22 | |||
52-Week Low Price | $0.04 | |||
52-Week Low Price (Date) | Jan 02, 2025 | |||
52-Week High Price (Date) | Jun 06, 2024 | |||
Valuation | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 9.16M | |||
Enterprise Value | 23.33M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.06 | |||
Earnings Per Share Growth | 1.97% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 4.09 | |||
Price/Book (Q) | -1.44 | |||
Enterprise Value/Revenue (TTM) | 12.24 | |||
Price | $0.05 | |||
Enterprise Value/EBITDA (TTM) | -5.65 | |||
Enterprise Value/EBIT | -5.42 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 162.03M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | -- | |||
Address | 82 Richmond Street East Toronto, ON M5C 1P1 | |||
Website | www.pharmacielo.com | |||
Country | Canada | |||
Year Founded | -- | |||
Profitability | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -225.93% | |||
Profit Margin | -541.54% | |||
Management Effectiveness | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -15.69% | |||
Return on Equity | -- | |||
Income Statement | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 1.90M | |||
Total Revenue (TTM) | 1.90M | |||
Revenue Per Share | $0.01 | |||
Gross Profit (TTM) | 18.30K | |||
EBITDA (TTM) | -4.12M | |||
EBIT (TTM) | -4.30M | |||
Net Income (TTM) | -10.31M | |||
Net Income Avl. to Common (TTM) | -10.31M | |||
Total Revenue Growth (Q YOY) | 271.59% | |||
Earnings Growth (Q YOY) | 5.83% | |||
EPS Diluted (TTM) | -0.06 | |||
EPS Diluted Growth (Q YOY) | 5.51% | |||
Balance Sheet | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 18.70K | |||
Cash Per Share (Q) | $0.00 | |||
Total Current Assets (Q) | 2.58M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -5.62M | |||
Current Ratio (Q) | 0.153 | |||
Book Value Per Share (Q) | -$0.03 | |||
Total Assets (Q) | 14.59M | |||
Total Current Liabilities (Q) | 16.93M | |||
Total Debt (Q) | 15.47M | |||
Total Liabilities (Q) | 20.21M | |||
Total Common Equity (Q) | -5.62M | |||
Cash Flow | PCLOF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 194.10K | |||
Cash from Financing (TTM) | 2.19M | |||
Net Change in Cash (TTM) | 2.20K | |||
Levered Free Cash Flow (TTM) | -3.58M | |||
Cash from Operations (TTM) | -2.39M | |||